TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Rhea-AI Summary

TRxADE HEALTH, INC. (NASDAQ: MEDS) received a notice of non-compliance from Nasdaq due to the failure to timely file its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance and can be granted up to 180 days to do so. TRxADE is working to complete the Form 10-Q and intends to file it as soon as possible.

Positive

• None.

Negative

• Received a notice of non-compliance from Nasdaq due to failure to timely file the Quarterly Report on Form 10-Q

TAMPA, FL, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of a pharmaceutical business-to-business exchange platform, announced today that it received a notice of non-compliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) on November 21, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).

Under Nasdaq’s listing rules, the Company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until May 20, 2024, to regain compliance.

The Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as practicable to regain compliance with the Rule.

About TRxADE HEALTH, INC.

TRxADE Health, Inc. is a parent company with various subsidiaries which include the pharmaceutical marketplace https://rx.trxade.com, and plant-based food www.superlatus.com.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. TRxADE intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements relate to future events or TRxADE’s future performance or future financial condition. These forward-looking statements are not historical facts but rather are based on current expectations, estimates, and projections about TRxADE, its industry, beliefs, and assumptions. Such forward-looking statements include, but are not limited to, statements regarding TRxADE’s or TRxADE’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future, including TRxADE ‘splans for and the potential benefits of the supplier agreement and the products, markets, and expected future performance and market opportunities of TRxADE. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond TRxADE’s control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; TRxADE’s ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; TRxADE’s ability to continue as a going concern; security interests under certain of TRxADE’s credit arrangements; TRxADE’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against TRxADE; unanticipated difficulties or expenditures relating to TRxADE’s business plan; and those risks detailed in TRxADE’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after that date, except as otherwise provided by law.

Investor Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
Email: info@skylineccg.com

FAQ

What is the ticker symbol for TRxADE HEALTH, INC.?

The ticker symbol for TRxADE HEALTH, INC. is MEDS.

When did TRxADE HEALTH, INC. receive a notice of non-compliance from Nasdaq?

TRxADE HEALTH, INC. received a notice of non-compliance from Nasdaq on November 21, 2023.

What is the deadline for TRxADE HEALTH, INC. to submit a plan to regain compliance with Nasdaq?

TRxADE HEALTH, INC. has 60 calendar days to submit a plan to regain compliance with Nasdaq.

How long can TRxADE HEALTH, INC. be granted to regain compliance with Nasdaq?

If the plan is accepted by Nasdaq, the company can be granted up to 180 calendar days to regain compliance.

What is TRxADE HEALTH, INC. working on to regain compliance with Nasdaq?

TRxADE HEALTH, INC. is working diligently to complete its Form 10-Q and intends to file it as soon as practicable to regain compliance with Nasdaq Listing Rule 5250(c)(1).